AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30157924 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg buprenorphine
Number of subjects: 51
Study 30157924 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg buprenorphine
Number of subjects: 51
Study 30157924 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 mg buprenorphine
Number of subjects: 51
Study 28653377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 226
Study 28653377 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 226
Study 28653377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HES and Ringer's acetate
Number of subjects: 226
Study 26362831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (beta-blocker)
Number of subjects: 805
Study 26362831 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin receptor blocker)
Number of subjects: 805
Study 26362831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (20 mg nebivolol/320 mg valsartan)
Number of subjects: 805
Study 26362831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 805
Study 26362831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 805
Study 23232993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐incision laparoscopic surgery (SILS) cholecystectomy
Number of subjects: 40
Study 23232993 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 40
Study 21709162 — intervention group
Group type: EXPERIMENTAL
Intervention: WIISARD (electronic pathway)
Number of subjects: 100
Study 21709162 — intervention group
Group type: COMPARATOR
Intervention: Control (paper-based pathway)
Number of subjects: 100
Study 17604930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-attenuation barium sulphate suspension
Number of subjects: 90
Study 17604930 — intervention group
Group type: COMPARATOR
Intervention: High-attenuation barium sulphate preparation
Number of subjects: 90
Study 16451158 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (130/0.4)
Number of subjects: 42
Study 16451158 — intervention group
Group type: COMPARATOR
Intervention: FFP (10 ml/kg)
Number of subjects: 42
Study 12721160 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH/IUI
Number of subjects: 0
Study 12721160 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 0
Study 12721160 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 11110875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 80
Study 11110875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9264047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet or Sinemet-CR (carbidopa-levodopa association) taken 0.5, 1, 2, 4, 8, 12 hours before collection
Number of subjects: 70
Study 1437922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (60 mg infusion over 2 hours)
Number of subjects: 0
Study 1437922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (infusions over 4, 8, or 24 hours)
Number of subjects: 0
Study 1437922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (various infusion rates)
Number of subjects: 0
Study 1437922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (short infusions)
Number of subjects: 0
Study 29067834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 72
Study 29067834 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 72
Study 28819922 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered cognitive behavior therapy/motivational interviewing (CBT/MI)
Number of subjects: 274
Study 28819922 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered CBT/MI with brief therapist assistance (SHADE CBT/MI)
Number of subjects: 274
Study 28819922 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (PCT)
Number of subjects: 274
Study 25908605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral S-1 plus cisplatin (80 mg/m2/day on days 1-21 plus cisplatin 60 mg/m2 on day 8 every 4-5 weeks)
Number of subjects: 608
Study 25908605 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (60 mg/m2 on day 1 plus cisplatin 80 mg/m2 on day 1 every 3-4 weeks)
Number of subjects: 608
Study 25908605 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 608
Study 25908605 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 608
Study 23778853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 26
Study 23778853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21191095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible reward
Number of subjects: 0
Study 21191095 — intervention group
Group type: EXPERIMENTAL
Intervention: Social reward
Number of subjects: 0
Study 21191095 — intervention group
Group type: EXPERIMENTAL
Intervention: No reward
Number of subjects: 0
Study 21191095 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 0
Study 18447222 — intervention group
Group type: EXPERIMENTAL
Intervention: Three needling method (acupuncture at Huantiao (GB 30), Yanglingquan (GB 34), Shenmai (BL 62), with needling at shallow, middle, and deep layers, followed by massage at the Foot‐Taiyang Channel and Foot‐Shaoyang Channel)
Number of subjects: 82
Study 18447222 — intervention group
Group type: COMPARATOR
Intervention: Routine needling (acupuncture at Huantiao (GB 30), Juliao (GB 29), Chengfu (BL 36), Yanglingquan (GB 34), followed by massage)
Number of subjects: 82
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine 120 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine 180 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Number of subjects: 42
Study 17345837 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 14570783 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia using propofol
Number of subjects: 305
Study 14570783 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anaesthesia using sevoflurane
Number of subjects: 305
Study 10781481 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine (4.5 mg/kg)
Number of subjects: 30
Study 10781481 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg)
Number of subjects: 30
Study 10781481 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 8635674 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmol/day sodium supplement (group 2)
Number of subjects: 16
Study 8635674 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (group 1)
Number of subjects: 16
Study 1425867 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Th) 450-900 mg in the evening
Number of subjects: 7
Study 1425867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1425867 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Th)
Number of subjects: 7
Study 2580168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol plus diuretic
Number of subjects: 97
Study 2580168 — intervention group
Group type: COMPARATOR
Intervention: Captopril plus diuretic
Number of subjects: 97
Study 29931657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IU)
Number of subjects: 65
Study 29931657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26351927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral melatonin (6 mg total: 3 mg loading dose at 9 pm + six 0.5 mg doses hourly)
Number of subjects: 13
Study 26351927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered using a similar regimen to melatonin)
Number of subjects: 13
Study 24732894 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (10 mg intravenous twice daily for 2 days before and 3 days after stenting)
Number of subjects: 114
Study 24732894 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 114
Study 24294573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with one in 200,000 adrenaline
Number of subjects: 30
Study 24294573 — intervention group
Group type: COMPARATOR
Intervention: Control group with one in 200,000 adrenaline in distilled water
Number of subjects: 30
Study 20938358 — intervention group
Group type: EXPERIMENTAL
Intervention: LG‐SM
Number of subjects: 0
Study 20938358 — intervention group
Group type: EXPERIMENTAL
Intervention: SM‐LG
Number of subjects: 0
Study 20938358 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 0
Study 16411223 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan followed by cisplatin (I-P)
Number of subjects: 80
Study 16411223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin followed by irinotecan (P-I)
Number of subjects: 80
Study 15314593 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered visual acuity testing using the EVA (Group A)
Number of subjects: 108
Study 15314593 — intervention group
Group type: COMPARATOR
Intervention: Full ATS protocol (Group B)
Number of subjects: 108
Study 11269893 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (25 to 100 mg trice daily for 24 weeks)
Number of subjects: 154
Study 11269893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 11269893 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 154
Study 9017770 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-diltiazem ER (dosage titrated to response, maximum of enalapril 10 mg-diltiazem ER 360 mg/day)
Number of subjects: 265
Study 9017770 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg-diltiazem ER 120 mg once/day (titrated to response)
Number of subjects: 265
Study 8300456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine-ISDN
Number of subjects: 153
Study 8300456 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 153
Study 8300456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 3520626 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance (experimental group)
Number of subjects: 50
Study 3520626 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study 30681971 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis L. based product (MO), 500 mg capsules, 2 capsules daily for 3 months
Number of subjects: 37
Study 30681971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 37
Study 28659346 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diets varying in macronutrient content
Number of subjects: 692
Study 28659346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 692
Study 25845978 — intervention group
Group type: COMPARATOR
Intervention: High-pressure, low-volume nasal saline (HPLVNS) irrigation
Number of subjects: 73
Study 25845978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure, high-volume nasal saline (LPHVNS) irrigation with fluticasone propionate (FP)
Number of subjects: 73
Study 24163425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl during exercise
Number of subjects: 9
Study 24163425 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (control) during exercise
Number of subjects: 9
Study 21114892 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-GI carbohydrates
Number of subjects: 25943
Study 21114892 — intervention group
Group type: COMPARATOR
Intervention: High-GI carbohydrates
Number of subjects: 25943
Study 21114892 — intervention group
Group type: COMPARATOR
Intervention: Low-GI carbohydrates
Number of subjects: 25943
Study 20104985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating depression scale (SDS)
Number of subjects: 560
Study 20104985 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating anxiety scale (SAS)
Number of subjects: 560
Study 20104985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anxiety and depression
Number of subjects: 560
Study 20104985 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression with anxiety
Number of subjects: 560
Study 20104985 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression with sub-anxiety
Number of subjects: 560
Study 17760599 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream used daily in conjunction with laser therapy
Number of subjects: 20
Study 17760599 — intervention group
Group type: COMPARATOR
Intervention: Placebo used daily in conjunction with laser therapy
Number of subjects: 20
Study 17760599 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 20
Study 17760599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16344026 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive neurorehabilitation program
Number of subjects: 19
Study 16344026 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 19
Study 11865364 — intervention group
Group type: COMPARATOR
Intervention: Glucose group
Number of subjects: 18
Study 11865364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat group
Number of subjects: 18
Study 11865364 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study 10510923 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional continuous magnetic stimulation (15-minute session at 20 Hz, 1-minute-on/30-second-off cycles)
Number of subjects: 10
Study 10510923 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no stimulation)
Number of subjects: 10
Study 7781653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g ascorbic acid (AA) and 0.2 g pantothenic acid (PA) supplementation
Number of subjects: 49
Study 7781653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 49
Study 2396603 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg
Number of subjects: 50
Study 2396603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 386677 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 137
Study 386677 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline
Number of subjects: 137
Study 31010241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 plus vitamin B6 (ZR)
Number of subjects: 23
Study 31010241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study 27412664 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual routine treatment with exercise training (n=44)
Number of subjects: 64
Study 27412664 — intervention group
Group type: COMPARATOR
Intervention: Usual routine treatment without training (n=20)
Number of subjects: 64
Study 26099752 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of 80 mg triamcinolone and 8 ml bupivacaine 0.25%
Number of subjects: 0
Study 26099752 — intervention group
Group type: COMPARATOR
Intervention: Epidural injection of 8 ml bupivacaine 0.25%
Number of subjects: 0
Study 23747802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inpatient physical training (aerobic + strength) for the duration of neoadjuvant chemotherapy, 3 weekly 60-70 min exercise sessions
Number of subjects: 60
Study 23747802 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 60
Study 23747802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined inpatient physical training (aerobic + strength)
Number of subjects: 60
Study 21238614 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific intervention using bouts of physical activity
Number of subjects: 0
Study 21238614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18575980 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life adjusted failure time estimators
Number of subjects: 0
Study 18575980 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing censoring mechanisms
Number of subjects: 0
Study 18575980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for recorded prognostic factors
Number of subjects: 0
Study 18575980 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization from single to many censoring processes
Number of subjects: 0
Study 17077058 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein high fibre snack bar
Number of subjects: 23
Study 17077058 — intervention group
Group type: COMPARATOR
Intervention: High fat high sugar snack bar
Number of subjects: 23
Study 15577047 — intervention group
Group type: EXPERIMENTAL
Intervention: Raroxifene treatment
Number of subjects: 0
Study 11439379 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steroid treatment
Number of subjects: 9
Study 11439379 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal intermittent fatigue protocol (0.6 duty cycle)
Number of subjects: 9
Study 11439379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal and submaximal relative integrated electromyogram (IEMG)
Number of subjects: 9
Study 11439379 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study 9924277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato purée (16.5 mg total lycopene)
Number of subjects: 10
Study 9924277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh raw tomato (16.5 mg total lycopene)
Number of subjects: 10
Study 9924277 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary portions of tomato purée (16.5 mg total lycopene) for 7 days
Number of subjects: 10
Study 9924277 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary portions of fresh raw tomato (16.5 mg total lycopene) for 7 days
Number of subjects: 10
Study 9924277 — intervention group
Group type: COMPARATOR
Intervention: Tomato purée
Number of subjects: 10
Study 9924277 — intervention group
Group type: COMPARATOR
Intervention: Fresh raw tomato
Number of subjects: 10
Study 8000625 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study 8000625 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 301
Study 2682096 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mezlocillin and 0.5 g metronidazole (one-shot dose)
Number of subjects: 90
Study 2682096 — intervention group
Group type: COMPARATOR
Intervention: Short-time prophylaxis (2 days)
Number of subjects: 90
Study 782698 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (NSC-409962)
Number of subjects: 47
Study 782698 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU maintenance therapy
Number of subjects: 47
Study 782698 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 47
Study 28493413 — intervention group
Group type: EXPERIMENTAL
Intervention: Family environment, network, parental socio‐economic status, self‐efficacy, proactive personality
Number of subjects: 250
Study 29025506 — intervention group
Group type: EXPERIMENTAL
Intervention: ENRICH program (8-week face-to-face intervention)
Number of subjects: 60
Study 25840952 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal left ventricular geometry (LVG)
Number of subjects: 1961
Study 22230353 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 15
Study 22230353 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution (PL)
Number of subjects: 15
Study 20049949 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation of mesalamine at 2.4 g/day
Number of subjects: 131
Study 20049949 — intervention group
Group type: COMPARATOR
Intervention: Time-dependent release formulation of mesalamine at 2.25 g/day
Number of subjects: 131
Study 20049949 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-dependent release formulation of mesalamine
Number of subjects: 131
Study 20049949 — intervention group
Group type: COMPARATOR
Intervention: Time-dependent release formulation of mesalamine
Number of subjects: 131
Study 19265453 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine 3 d (AL)
Number of subjects: 0
Study 19265453 — intervention group
Group type: COMPARATOR
Intervention: artesunate monotherapy 7 d (AS7)
Number of subjects: 0
Study 19265453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 0
Study 15726272 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral repetitive magnetic stimulation (rMS)
Number of subjects: 53
Study 15726272 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 53
Study 15726272 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 53
Study 12093428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition
Number of subjects: 84
Study 12093428 — intervention group
Group type: COMPARATOR
Intervention: Control nutrition (isonitrogenous, isoenergetic)
Number of subjects: 84
Study 15613202 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation imagery techniques
Number of subjects: 10
Study 15613202 — intervention group
Group type: COMPARATOR
Intervention: Conventional pharmacotherapy
Number of subjects: 10
Study 7555918 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 30
Study 7555918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decaffeinated coffee)
Number of subjects: 30
Study 2028366 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day tetracycline regimen
Number of subjects: 918